All 10 pharmaceutical companies selected for Medicare drug price negotiations have agreed to participate, despite some having previously sued to halt the process. President Joe Biden’s Inflation Reduction Act enabled Medicare to negotiate drug prices for the first time, with the negotiations expected to conclude in August 2024, and reduced prices taking effect in January… Continue reading Drugmakers opt in to Medicare drug price negotiations – here’s what happens next

The company is working on a treatment of alpha-1 antitrypsin deficiency, which it claims it can deliver direct to lung cells via a nebulizer.

Since 2019, Generate has raised nearly $700 million in private financing and has now brought a monoclonal antibody into Phase 1 testing.

“There is a light wind for benefit, and no wind for risk,” said one adviser who voted with eight others to recommend the biotech’s drug Onpattro for cardiomyopathy of ATTR amyloidosis.

The biotech is telling investors it expects to launch as many as 15 new products in five years, a bold goal that will require a lot to go right to pull off.

The digital therapeutics company expects to extend its cash runway into 2025 with the changes.

This fall will now feature vaccination campaigns for COVID-19, influenza and respiratory syncytial virus.

The two-year-old San Diego biotech is allied with The Jackson Laboratory to engineer better mouse models of the rare diseases it plans to target.

Citing “near-term headwinds,” the cancer cell therapy developer will lay off 176 employees and pare back spending.

Acelyrin’s share value collapsed Tuesday after its lead drug fell short in the company’s first big trial test since it raised $540 million in a May IPO.

Arialys Therapeutics launched Tuesday with $58 million in funding from a group of life sciences investors that includes Johnson & Johnson’s venture arm.

The deal will give the pharma’s Alexion unit access to Verge Genomics’ platform, which uses human tissue data to find drug targets for diseases that degrade the nerve system.